Fail

Discussion in 'Lundbeck' started by anonymous, Sep 22, 2016 at 2:49 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Has anyone ever been at a company with this bad of a future?

    Walking dead.
     

  2. anonymous

    anonymous Guest

    It will be interesting to see when and how much they shrink the neuro sales force. Do they wait until Sabril LOE, or do they blow things up this year?
     
  3. anonymous

    anonymous Guest

     
  4. anonymous

    anonymous Guest

    If US management gets to decide:
    -All that matters is hitting 1 billion 2016, thus status quo in sales force with huge reorg in 2017 with IDL failure as justification.

    If HQ decides:
    -No reason to pay 2016 T3 or annual bonuses on employees they will have to be let go in early 2017, thus big cuts ASAP in 2016.
     
  5. anonymous

    anonymous Guest

    No need for them to rush to layoffs. My guess is that attrition will dramatically increase on it's own, now that everyone is recognizing the fact that staying here is not exactly a brilliant career move. Morale is horrible. People are just going through the motions. I think the massive increase in the Rex goals, the grid, no pipeline, and everything else that's wrong, might have been actually planned to run people off. Gamma has not produced a damn thing, so they will likely be first to go. Alpha is unneeded. Just add AM to the mix of Rex and Trin. Alpha has never, nor will they ever sell Trin., and their scam on upper management that they do, is hilarious!

    Ultimately, neuro and psych will be one team, unless the company folds. The question is, will you have a chair (if you want one!) when the music stops?
     
  6. anonymous

    anonymous Guest

    Abilify Maintena share will be over 100 million in 2017 (our cut)

    60 AM's to generate this.

    You do the math. Looks much better then being 1 of 350 selling Trint.
     
  7. anonymous

    anonymous Guest

    From the 2nd QTR report:
    IN THE U.S.

    "Abilify Maintena continues to grow and sales reached DKK 110 million for the quarter, which represents Lundbeck’s 20% share of total net sales." FOR THE FIRST HALF OF 2016, SALES WERE DKK 215 MILLION. So say for the whole year, sales may be around DKK 430 million, or roughly U.S. $69 million. Trin, the 1st half of 2016 in the U.S. was DKK 262 million. The real question is, what is the amount of profit that's being generated for each drug. AM is very expensive, lie Rex. Sales #'s don't tell the whole picture.
     
  8. anonymous

    anonymous Guest

    Sorry my friend, you aren't selling many units.
     
  9. anonymous

    anonymous Guest

    Stupid shits like you need to be the first to go. You spew your bullshit with nothing to back it up. Just empty words from an empty suit. Don't presume to know what others do,when you don't even try to work. The whole industry is in the shitter and you need to be the first turd flushed!
     
  10. anonymous

    anonymous Guest

    You don't have many insider contacts do you? The Reaper is coming...
     
  11. anonymous

    anonymous Guest

    The Reaper is Hillary Clinton and she is coming for all of Pharma. Lundbeck will fall with the whole industry when our healthcare system becomes government single payer. Formulary driven not market driven will mean the end of all our sales and marketing jobs. Lundbeck is as safe as anywhere else for the near future.
     
  12. anonymous

    anonymous Guest

    If you were on Glover's call, you'd have seen that if all 3 psych drugs hit forecast, we'd have about 300 million or so. For those of you that haven't figured out the disconnect between psych sales and hitting a billion dollars, it is simple. Neuro drives the company and its biggest drug went off patent last year. It's 2nd biggest drug goes off patent in the near future. This company doesn't have the revenue to continue as it is currently structured. Can I make it any clearer?